Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The antiviral effect of interferon-beta against SARS-Coronavirus is not mediated by MxA protein

Martin Spiegel a, Andreas Pichlmair a, Elke Mühlberger b, Otto Haller a, Friedemann Weber a,∗

a Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, D-79008 Freiburg, Germany
b Institut für Virologie der Philipps-Universität Marburg, 35037 Marburg, Germany

Received in revised form 6 November 2003; accepted 14 November 2003

Abstract

Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus termed SARS-CoV. No antiviral treatment has been established so far. Interferons are cytokines which induce the synthesis of several antivirally active proteins in the cell. In this study, we demonstrated that multiplication of SARS-CoV in cell culture can be strongly inhibited by pretreatment with interferon-beta. Interferon-alpha and interferon-gamma, by contrast, were less effective. The human MxA protein is one of the most prominent proteins induced by interferon-beta. Nevertheless, no interference with SARS-CoV replication was observed in Vero cells stably expressing MxA. Therefore, other interferon-induced proteins must be responsible for the strong inhibitory effect of interferon-beta against SARS-CoV.

© 2003 Elsevier B.V. All rights reserved.

Keywords: SARS-Coronavirus; Interferon; MxA protein; Virus inhibition

1. Introduction

Severe acute respiratory syndrome (SARS) is an infectious disease which has recently emerged in China and rapidly spread to other countries (Chan et al., 2003). To date, 8098 cases with 774 deaths are reported (WHO, 2003). Intensive research has led to the identification of a positive-stranded RNA virus, termed SARS-coronavirus (SARS-CoV), as the etiologic agent (Drosten et al., 2003; Fouchier et al., 2003; Ksiazek et al., 2003; Kuiken et al., 2003; Peiris et al., 2003).

Virus infection of mammalian cells prompts the innate immune system to establish a first line of defense. Interferons (IFNs) play a key role in these events, since they activate the innate immune system and help to shape adaptive immunity (Stark et al., 1998). Two types of IFNs are involved in establishing an antiviral state. Type I IFN (IFN-α/β) is synthesized by most cell types as a direct response to virus infection, whereas type II IFN (IFN-γ) is produced by immune cells after contact with antigen-presenting cells. Both type I and type II IFNs induce the synthesis of distinct but partially overlapping sets of mRNAs which encode proteins with antiviral, antiproliferative, and immunomodulatory properties (de Veer et al., 2001). Among the type I IFN-induced proteins, the main antiviral factors are the Mx proteins (Haller and Kochs, 2002). Mx proteins inhibit virus replication at early stages of infection by affecting transcription and/or replication of the viral genome (Haller and Kochs, 2002).

In this study, we investigated the potential of different IFNs to inhibit replication of SARS-CoV in cell culture and determined whether the human MxA protein contributes to the antiviral effect of type I IFNs.

Abbreviations: IFN, interferon; PFU, plaque forming units; PKR, protein kinase R; SARS, severe acute respiratory syndrome; SARS-CoV, SARS-associated coronavirus

∗ Corresponding author. Tel.: +49-761-203-6614; fax: +49-761-203-6562.
E-mail address: FWEBER@UKL.UNI-FREIBURG.DE (F. Weber).

1386-6532/$ – see front matter © 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.jcv.2003.11.013
2. Methods

2.1. Cells and viruses

African green monkey kidney (Vero) cells were grown in Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum. Vero cell clones VA3, VA9, and VA12 which are permanently transfected with MxA expression plasmids (Frese et al., 1995) were grown in the same medium plus 2 mg of G418 per ml. The FFM-1 isolate of SARS-CoV was kindly provided by Stephan Becker, University of Marburg, Germany.

2.2. Interferons

Human IFN-α A/D (BglII), pegylated human IFN-α, IFN-β, and IFN-γ were purchased from PBL Biomedical Laboratories, Griffith Micro Science, Schering and Sigma, respectively.

2.3. Plaque assays

Virus plaque assays were performed as described previously (Frese et al., 1995). Briefly, Vero cell monolayers were infected with dilutions of supernatants from infected cells, overlaid with soft agar, and allowed to form plaques for 72 h. Then the agar overlay was removed and cells were stained with a solution of 1% crystal violet, 3,6% formaldehyde, 1% methanol, and 20% ethanol.

3. Results and discussion

3.1. Inhibitory effects of interferons

We investigated the inhibitory effect of type I and II IFNs on SARS-CoV multiplication in cell culture. We used universal IFN-α A/D (BglII), pegylated human IFN-α, human IFN-β, and human IFN-γ. These cytokines are known to inhibit the replication of several pathogenic viruses in cell culture or in patients (Samuel, 2001). For all following experiments, Vero cells were chosen because they are unable to synthesize IFN but are fully responsive to IFN treatment (Diaz et al., 1988). Therefore, any additional effects of virus-induced IFN that would bias the results can be excluded. Cells were pretreated with the IFNs, infected with SARS-CoV, and virus in the supernatant was determined after overnight incubation. Fig. 1 shows that administration of IFN-α and IFN-γ led to a 10-fold inhibition of virus growth. IFN-β was even more potent since it resulted in a 1000-fold reduction of virus titers. We also tested tumor necrosis factor (TNF) but found no inhibitory effect (data not shown). These data are in agreement with a recent report by Cinatl et al. (2003) and demonstrate that IFN-β is the most effective antiviral cytokine against SARS-CoV.

3.2. Virus replication in MxA-expressing cells

Mx is one of the main IFN-α/β-induced proteins which are antivirally active. Previous gene array analyses have revealed that the mRNA for the human MxA protein is induced 31-fold by IFN-β, 21-fold by IFN-α, and not at all by IFN-γ (Der et al., 1998). Due to the similarity of the antiviral effect of the different IFNs (see Fig. 1) and the pattern of MxA expression, it was suspected that MxA might be the responsible factor (Cinatl et al., 2003). Therefore, we Fig. 2. Growth of SARS-CoV in MxA-expressing cells. (A) Viral titers. Vero cell lines expressing MxA (VA3, VA9, VA12) and control cells (Vero, VN36) were infected with SARS-CoV at a multiplicity of infection of 1, and viral titers in the supernatants were determined at 48 h post-infection. Mean values and standard deviations of three independent experiments are shown. The same batches of MxA-expressing cells potently suppress growth of Thogoto-orthomyxoviruses, as published previously (Frese et al., 1995). (B) Plaque formation. Monolayers of 10⁶ Vero cells (left) and MxA-expressing VA9 cells (right) were infected with 20 PFU of SARS-CoV and overlaid with soft agar.
tested growth of SARS-CoV in Vero cell lines which sta-
ble express MxA (Frese et al., 1995). These cells are widely
used to demonstrate the antiviral effect of MxA against a
range of RNA viruses (Haller and Kochs, 2002). The Vero
cells expressing MxA (V43, V9, V12) and control cells
(VN36, Vero) were infected with the SARS-CoV isolate
FFM-1, and viral titers in the supernatants were determined
at 48 h post-infection. As depicted in Fig. 2A, no appar-
ent differences in virus growth were detected. In all cases
titers of approximately 108 infectious particles per ml were
reached. Likewise, when MxA-expressing V43 and control
Vero cells were directly used in a plaque assay, no differ-
ences in the efficiency of plaque formation or size were ob-
served (Fig. 2B). These results suggest that MxA is not the
critical factor that mediates inhibition of SARS-CoV, de-
spite its high-level induction by IFN-β. Thus, the search for
antiviral effects against SARS-CoV should focus on other
IFN-induced proteins such as PKR or RNase L.

Acknowledgements

We thank Stephan Becker for the generous gift of
SARS-CoV isolate FFM-1. Work in the authors’ laborato-
ries is supported by grants from the Deutsche Forschungs-
gemeinschaft.

References

Chan HL, Tsui SK, Sung JJ. Coronavirus in severe acute respiratory
syndrome (SARS). Trends Mol Med 2003;9:323–5.
Cinatul J, Morgenstern B, Baier G, Chandoo P, Rabenau H, Doer H. Treatment of SARS with human interferons. Lancet 2003;362:203–4.
Diaz MO, Zemin S, Le Brou MM, Pitha P, Smith SD, Chilcote RR, Bowley JD. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 1995;85:5259–63.
Drosten C, Gunther S, Prissier W, van der Werf S, Brodh HR, Becker S, Rabenau H, Panning M, Kolomenska L, Foscher RA, Berger A, Buehner MA, Czajt J, Elneck M, Etschen U, Gjesen K, Kramme S, Mangenver H, Moller R, Rickers V, Sturmer M, Venezuela S, Klein HM, Osterhaus AD, Schmitz H, Doer HR. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967–76.
Frese M, Kochs G, Meier-Dieter U, Siebler J, Haller O. Human MxA protein inhibits tick-borne Thogoto virus but not Dheri virus. J Virol 1995;69:1004–9.
Haller O, Kochs G. Interferon-induced Mx proteins: dynamite-like GT-
Cases with antiviral activity. Traffic 2003;3:716–7.
Ksiaetz TG, Erlman D, Goldsmith CS, Zaki SR, Petet T, Emsky S, Tong S, Urban C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling AE, Humphery CD, Shirk W, Graener J, Paddock CD, Rota P, Fields D, DelRio J, Yang JY, Cox N, Hughes JM, DeDuc JW, Bellini WJ, Anderson LJ. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953–66.
Kulken T, Foscher RA, Schitten M, Romenclava GS, van Amerongen G, van de Riet D, Laman JD, de Jong T, van Doermum G, Lim W, Ling AE, Chan PK, Tam JS, Zambo MC, Gopal R, Drosten C, van der Werf S, Etschen U, Mangenver H, Sturker J, Prissier JS, Osterhaus AD. Newly discovered coronaviruses as the primary cause of severe acute respiratory syndrome. Lancet 2003;362:263–70.
Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yue WK, Yan WW, Cheung MT, Chung VC, Chan RH, Tsang DN, Yong RW, Ng TK, Young KY. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361:1319–25.
Samuels CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;4:776–109.
Silverman RH. Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action. J Interferon Res 1994;14:101–4.
Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998;67:227–64.
WHO. 2003. Summary table of SARS cases by country, 1 Novem-
ber 2002–26 September 2003. http://www.who.int/csr/sars/country/
table2003_09_26/en/.
Williams BR. PKR: a sentinel kinase for cellular stress. Oncogene 1999;18:612–20.